StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.50−0.44 (-2.21%)

Close on Nov 18, 2026Market cap $5.51BP/E –Yield –

Caris Life Sciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Caris Life Sciences's operating income for the twelve months ending Sep 30, 2026 was $139.94M. For fiscal 2025 it was $45.11M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$45.11M–
FY2024Dec 31, 2024-$257.12M–
FY2023Dec 31, 2023-$319.55M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$19.32M-40.8%
Q2 FY2026Jun 30, 2026$26.93M–
Q1 FY2026Mar 31, 2026$5.28M–
Q4 FY2025Dec 31, 2025$88.41M–
Q3 FY2025Sep 30, 2025$32.64M–
Q2 FY2025Jun 30, 2025-$17.99M–
Q1 FY2025Mar 31, 2025-$57.95M–
Q4 FY2024Dec 31, 2024-$37.05M–
Q3 FY2024Sep 30, 2024-$60.84M–
Q2 FY2024Jun 30, 2024-$67.01M–

More Caris Life Sciences figures

See a number that looks wrong?